Furthermore, the similar clinicopathology between LS and LiP has allowed for considerable progress in addressing the in vivo biological function of this attractive molecule in animal model studies using a passive transfer of anti-ECM1 antibodies, and gene knockout and transgenic systems targeted for ECM1 in mice and zebrafish [30,31,32,33]. Here, ECM1 is linked to medical procedure.